James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

For-Profit Colleges Have Little Blood Left to Give

Corinthian Colleges, ITT Educational Services, and other for-profit colleges look like a lost cause in their current state.

5 Buy-and-Hold-Forever Dividend Stocks

The market's recent pullback has cranked up yields, and income investors may want to go shopping for dividend stocks. Here are five worth a look.

Big Data Gets Personal, Moving Past the Point of No Return

Wal-Mart is the last of the major retailers to use big data to personalize its online sales pitch, proving that the practice is the new norm.

EBAY Stock Further Blurs the Line Between Tech and Financials

Anyone who owns or may soon own EBAY stock may be wondering what's at stake for the company. Here's some food for thought.

Should AGN Just Take the Offer From Bill Ackman and VRX?

Bill Ackman and Valeant Pharmaceuticals have teamed up to acquire Allergan, but the saga isn't as simple as it seems. Here's the deal on AGN.